|  |  |  | **Vaccine brand** | | | |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **Moderna** | | **Pfizer** | |
|  |  |  | **Exposed** | | | |
| Variable name | Variable level | Estimate name | Unexposed | Exposed | Unexposed | Exposed |
| Number records | - | N | 1,679 | 1,679 | 6,819 | 6,819 |
| Age | - | Median [Q25 - Q75] | 31.00 [27.00 - 35.00] | 31.00 [27.00 - 35.00] | 33.00 [29.00 - 36.00] | 33.00 [29.00 - 36.00] |
| Age group | 12 to 24 | N (%) | 224 (13.3%) | 222 (13.2%) | 675 (9.9%) | 670 (9.8%) |
|  | 25 to 39 | N (%) | 1,362 (81.1%) | 1,372 (81.7%) | 5,483 (80.4%) | 5,488 (80.5%) |
|  | 40 to 55 | N (%) | 93 (5.5%) | 85 (5.1%) | 661 (9.7%) | 661 (9.7%) |
| Vaccine brand | Moderna | N (%) | 1,679 (100.0%) | 1,679 (100.0%) | - | - |
|  | Pfizer | N (%) | - | - | 6,819 (100.0%) | 6,819 (100.0%) |
| Trimester | Trimester 1 | N (%) | 513 (30.6%) | 513 (30.6%) | 1,681 (24.7%) | 1,682 (24.7%) |
|  | Trimester 2 | N (%) | 657 (39.1%) | 640 (38.1%) | 2,828 (41.5%) | 2,816 (41.3%) |
|  | Trimester 3 | N (%) | 509 (30.3%) | 526 (31.3%) | 2,310 (33.9%) | 2,321 (34.0%) |
| Number visits prior year | - | Median [Q25 - Q75] | 16.00 [8.00 - 29.00] | 30.00 [16.00 - 50.00] | 17.00 [9.00 - 29.00] | 32.00 [18.00 - 54.00] |
| Number prior pregnancies | - | Median [Q25 - Q75] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] |
| Conditions any time prior | Anemia | N (%) | 446 (26.6%) | 385 (22.9%) | 1,708 (25.0%) | 1,521 (22.3%) |
|  | Heart conditions | N (%) | 29 (1.7%) | 37 (2.2%) | 141 (2.1%) | 169 (2.5%) |
|  | Eclampsia preeclampsia | N (%) | 20 (1.2%) | 24 (1.4%) | 65 (1.0%) | 70 (1.0%) |
|  | Asthma | N (%) | 86 (5.1%) | 108 (6.4%) | 358 (5.3%) | 419 (6.1%) |
|  | Pneumonia | N (%) | 46 (2.7%) | 63 (3.8%) | 198 (2.9%) | 221 (3.2%) |
|  | Hypothyroidism | N (%) | 106 (6.3%) | 131 (7.8%) | 570 (8.4%) | 622 (9.1%) |
|  | Depressive disorder | N (%) | 87 (5.2%) | 93 (5.5%) | 382 (5.6%) | 398 (5.8%) |
|  | Gestational diabetes | N (%) | 81 (4.8%) | 87 (5.2%) | 418 (6.1%) | 412 (6.0%) |
|  | Chronic hypertension | N (%) | 33 (2.0%) | 41 (2.4%) | 138 (2.0%) | 161 (2.4%) |
|  | Anxiety disorder | N (%) | 449 (26.7%) | 449 (26.7%) | 1,909 (28.0%) | 1,892 (27.7%) |
|  | Chronic obstructive lung disease | N (%) | 0 (0.0%) | <5 (<5%) | <5 (<5%) | 9 (0.1%) |
| Drugs prior 180 days | Propulsives | N (%) | 61 (3.6%) | 74 (4.4%) | 270 (4.0%) | 260 (3.8%) |
|  | Progestogens | N (%) | 81 (4.8%) | 95 (5.7%) | 372 (5.5%) | 363 (5.3%) |
|  | Antimycotics systemic | N (%) | 5 (0.3%) | 10 (0.6%) | 33 (0.5%) | 36 (0.5%) |
|  | Estrogens | N (%) | 132 (7.9%) | 114 (6.8%) | 477 (7.0%) | 490 (7.2%) |
|  | Antithrombotics | N (%) | 113 (6.7%) | 82 (4.9%) | 332 (4.9%) | 298 (4.4%) |
|  | Antihistamines systemic | N (%) | 243 (14.5%) | 285 (17.0%) | 990 (14.5%) | 1,057 (15.5%) |
|  | Antidepressants | N (%) | 73 (4.3%) | 84 (5.0%) | 330 (4.8%) | 373 (5.5%) |
|  | Immunoglobulins | N (%) | 57 (3.4%) | 48 (2.9%) | 305 (4.5%) | 285 (4.2%) |
|  | Analgesics and antipyretics | N (%) | 580 (34.5%) | 582 (34.7%) | 2,273 (33.3%) | 2,328 (34.1%) |
|  | Antiinflammatory antirehumatic | N (%) | 265 (15.8%) | 280 (16.7%) | 1,040 (15.3%) | 1,007 (14.8%) |
|  | Antiepileptics | N (%) | 18 (1.1%) | 43 (2.6%) | 93 (1.4%) | 99 (1.5%) |
|  | Antibacterials systemic | N (%) | 413 (24.6%) | 412 (24.5%) | 1,546 (22.7%) | 1,574 (23.1%) |